Completed PHASE3 INTERVENTIONAL NCT00004402

Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis

Sponsor: FDA Office of Orphan Products Development

Interventions calcitriol interferon gamma

Updated 5 times since 2017 Last updated: Mar 24, 2015 Started: Nov 30, 1999 Completion: Jun 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteopetrosis, this trial is completed. The trial is conducted by FDA Office of Orphan Products Development and has accumulated 5 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

FDA Office of Orphan Products Development
Medical University of South Carolina

Data source: FDA Office of Orphan Products Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.